Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Scusami who wrote (13923)	1/30/1998 7:37:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Scusami, I don't think that the inhaler news has anything to do with LGND's price. The inhaler news was also in the NY Times report and its not really new. LGND's diabetes compounds are oral. Inhaler news would have more of an effect on companies that rely on injected drugs (like LLY's insulin) and it would put more pressure on LLY to develop oral compounds like Targretin. I suspect that technical factors and margin calls are providing the recent selling pressure.

To: Scusami who wrote (13923)	1/30/1998 8:12:00 AM
From: tonyt	Read Replies (3) \| Respond to of 32384

> I would consider anything that low to be a buying opportunity from > both trading and long term points of view. It might be worthwhile to factor in past performance of LGND in the 1st half of '96 and '97 (spring and summer historically are not good times for biotechs -- however, past performance, is no guarantee, so '98 could be different). Also might be worthwhile to post a 1998 timeline for milestones and expected news (has this been done yet?) BTW, How many 'buying opportunities' have we seen in the last 3 months? -- Don't try to catch a falling knife, wait till it hits the floor.